Skip to main content
. 2017 Sep 22;61(10):e00904-17. doi: 10.1128/AAC.00904-17

FIG 2.

FIG 2

In vivo efficacy of TRL1068 with or without vancomycin (VAN) in a rat infective endocarditis model due to MRSA. Median and quartile values are shown, with outliers being denoted by circles. (A) Bacterial burdens of vegetation at the primary site of infection were significantly reduced by 2 logs when TRL1068 was added to vancomycin. (B) An ∼1-log reduction of infection was seen at secondary infection sites. (C) Combination therapy resulted in reduced mortality.